ABSTRACT OF THE WEEK

Animals : an open access journal from MDPI
Volume 12 | Issue 3 (February 2022)

Lessons and Recommendations from a Pentobarbital Shortage: US and Canada 2021.

Animals (Basel). February 2022;12(3):.

Kathleen Cooney¹, Lianna Titcombe²

¹ Companion Animal Euthanasia Training Academy, Loveland, CO 80538, USA.; ² Companion Animal Euthanasia Training Academy, Loveland, CO 80538, USA.

Abstract

In 2021, a shortage in the supply of the euthanasia drug pentobarbital sodium affected animal care professionals around the world, including in the United States and Canada. Pentobarbital sodium is the drug of choice for companion animal euthanasia in both countries. The decreased availability of pentobarbital sodium affected a number of animal care industries, forcing conservation of the drug and the use of alternative methods and other agents to facilitate humane death for all manner of animal species. Veterinary medical groups, laboratory research institutions, and the animal sheltering industry worked together to identify the best path forward to maintain routine euthanasia practices and to protect the welfare of animals. This article aims to explore the reasons behind the shortage and to highlight the necessary responses and adjustments made in order to continue providing euthanasia services in North America. Recommendations for handling future pentobarbital shortages are included.

Keywords

euthanasia; humane death; pentobarbital sodium;

Article Tools:

Medline

Email to me

Archives Highlights:

Case series of maggot debridement therapy demonstrates safety and efficacy for treating problematic wounds in cats and dogs in Mexico.
Treatment was administered by applying 8-10 larvae per square cm surface area directly on the wound bed and covering the wound with a sterile polyester mesh, sutured to the skin. These were left on the wound for cycles of approximately 48 hours (24-72 hours); the cycles were repeated if more than 20% necrotic tissue remained after treatment. Review of these cases revealed that 80% of treated wounds achieved 100% debridement within 48-96 hours of treatment.

'Transmission Tracker - Dirofilaria'- a public dashboard to assess in real-time the temperature-bounded transmissibility of canine heartworm across Australia.
'Transmission Tracker - Dirofilaria' processes near real-time temperature records across Australia and allows users to enquire about historical and current weather suitability for canine heartworm transmission at any Australian postcode of their interest. This information allows veterinarians to access when, and for how long, heartworm may be transmitted at a specific location, assess the associated risk of infection, and advise on a patient-dependent dirofilariosis prevention plan for their canine patients and guardians.

Recovery of ambulation in small, nonbrachycephalic dogs after conservative management of acute thoracolumbar disk extrusion.
Forty-nine of fifty-one (96%) of deep pain-positive and 10/21 (48%) of deep pain-negative dogs recovered ambulation within the 12-week period. The median time to ambulation was 11 and 25 days for deep pain-positive and -negative dogs, respectively. Reduction in spinal cord compression varied among individuals from minimal to complete and apparently was unrelated to the recovery of ambulation.

Feline acute patient physiologic and laboratory evaluation scores and other prognostic factors in cats with first-time diabetic ketoacidosis.
Median BG was significantly higher in non-survivors (431 mg/dL) compared with survivors (343 mg/dL) and BG predicted mortality. For every 1 mg/dL increase in BG, the odds of death increased by 1.004.

Topical and oral emodepside formulations for last-line treatment of multianthelmintic drug-resistant hookworms when given orally to dogs are not bioequivalent.
This study was conducted in 3 phases, during which dogs received single doses of emodepside as the feline topical solution (1 mg/kg) orally, the canine modified-release tablet (1 mg/kg) orally, and the topical feline solution (3 mg/kg) topically. The feline topical solution administered orally at 1 mg/kg is not bioequivalent to the canine modified-release tablet. Markedly higher absorption of the feline topical solution administered orally raises potential safety concerns for extra-label use in dogs to treat multi-anthelmintic drug-resistant hookworm infections. Poor absorption following topical administration suggests it may be unsuitable for treating multi-anthelmintic drug-resistant hookworm infections.